Dana Investment Advisors Inc. Acquires 8,009 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Dana Investment Advisors Inc. boosted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 55.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 22,407 shares of the company’s stock after buying an additional 8,009 shares during the quarter. Dana Investment Advisors Inc.’s holdings in TransMedics Group were worth $1,397,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. Arizona State Retirement System grew its position in TransMedics Group by 1.9% during the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company’s stock valued at $603,000 after buying an additional 184 shares during the period. Venturi Wealth Management LLC grew its position in TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after buying an additional 219 shares during the period. National Bank of Canada FI grew its position in TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after buying an additional 262 shares during the period. Quarry LP grew its position in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Price Performance

TMDX stock opened at $67.46 on Friday. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company’s fifty day moving average price is $68.30 and its 200-day moving average price is $97.72. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a market capitalization of $2.27 billion, a PE ratio of 71.77 and a beta of 2.12.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Canaccord Genuity Group lowered their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. TD Cowen lowered their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Piper Sandler lowered their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.